Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying erlotinib to see how well it works in treating patients with
persistent or recurrent cancer of the cervix. Biological therapies such as erlotinib may
interfere with the growth of tumor cells and slow the growth of the tumor